Compare DERM & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DERM | PIM |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 159.5M |
| IPO Year | 2021 | N/A |
| Metric | DERM | PIM |
|---|---|---|
| Price | $5.07 | $3.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.67 | N/A |
| AVG Volume (30 Days) | ★ 154.6K | 66.2K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.28% |
| EPS Growth | ★ 34.72 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $61,858,000.00 | N/A |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | N/A |
| P/E Ratio | ★ N/A | $64.00 |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $3.14 |
| 52 Week High | $9.56 | $3.50 |
| Indicator | DERM | PIM |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 59.39 |
| Support Level | $4.85 | $3.29 |
| Resistance Level | $5.50 | $3.36 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 41.82 | 89.58 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.